IGMS

IGM Biosciences Inc

Add to Watchlist

Advanced Chart

1.260

-0.01(-0.787%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.280

Open

1.270

VWAP

Vol

2.59M

Mkt Cap

75.84M

Low

1.260

Amount

EV/EBITDA(TTM)

Total Shares

59.02M

-75.67M

EV/OCF(TTM)

P/S(TTM)

28.79

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

430.00K

+4.37%

420.00K

-18.6%

400.00K

-68.1%

Estimates Revision

The market is revising Upward the revenue expectations for IGM Biosciences, Inc. (IGMS) for FY2025, with the revenue forecasts being adjusted by 25.34% over the past three months. During the same period, the stock price has changed by -3.08%.

Revenue Estimates for FY2025

Revise Upward

+25.34%

In Past 3 Month

Stock Price

Go Down

-3.08%

In Past 3 Month

2 Analyst Rating

-0.79% Downside

Wall Street analysts forecast IGMS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGMS is 1.25 USD with a low forecast of 1.00 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

2 Hold

0 Sell

Hold

-0.79% Downside

Current: 1.260

Low

1.00

Averages

1.25

High

1.50

-0.79% Downside

Current: 1.260

Low

1.00

Averages

1.25

High

1.50

BofA

Underperform -> No Rating

downgrade

$1.247

2025-07-01

Reason

BofA

Price Target

$1.247

2025-07-01

downgrade

Underperform -> No Rating

Reason

BofA moves to No Rating from Underperform on IGM Biosciences after the company announced an agreement to be acquired by Concentra Biosciences for $1.247 per share in cash and a variable non-tradable contingent value right. IGM shares are no longer trading on fundamentals following the deal announcement, the analyst says.

Truist

Hold

downgrade

$2 -> $1

2025-06-11

Reason

Truist

Price Target

$2 -> $1

2025-06-11

downgrade

Hold

Reason

Truist lowered the firm's price target on IGM Biosciences to $1 from $2 and keeps a Hold rating on the shares. The firm has updated tis model to reflect Q1 financial results and the company's forward outlook, adding that it is waiting for any potential announcement regarding a strategic pivot from the company, the analyst tells investors in a research note.

JP Morgan

Eric Joseph

Sell

Hold

Upgrades

n/a

2025-01-13

Reason

JP Morgan

Eric Joseph

Price Target

n/a

2025-01-13

Upgrades

Sell

Hold

Reason

BMO Capital

Etzer Darout

Buy

Hold

Downgrades

$21 → $2

2025-01-10

Reason

BMO Capital

Etzer Darout

Price Target

$21 → $2

2025-01-10

Downgrades

Buy

Hold

Reason

RBC Capital

Brian Abrahams

Buy

Hold

Downgrades

$20 → $1.5

2025-01-10

Reason

RBC Capital

Brian Abrahams

Price Target

$20 → $1.5

2025-01-10

Downgrades

Buy

Hold

Reason

RBC Capital analyst Brian Abrahams downgraded IGM Biosciences to Sector Perform from Outperform with a price target of $1.50, down from $20. Following the company's decision to discontinue its primary value-driving IgM-based bispecific autoimmune clinical pipeline, reduce workforce by 73%, and seek strategic alternatives, RBC expects sharp downside for shares and expects the stock to settle in around anticipated cash levels one year out, the analyst tells investors in a research note.

Stifel

Stephen Willey

Strong Buy

Hold

Downgrades

$27 → $2.5

2025-01-10

Reason

Stifel

Stephen Willey

Price Target

$27 → $2.5

2025-01-10

Downgrades

Strong Buy

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for IGM Biosciences Inc (IGMS.O) is -0.88, compared to its 5-year average forward P/E of -6.43. For a more detailed relative valuation and DCF analysis to assess IGM Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.43

Current PE

-0.88

Overvalued PE

-0.11

Undervalued PE

-12.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.49

Current EV/EBITDA

0.49

Overvalued EV/EBITDA

1.66

Undervalued EV/EBITDA

-6.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

72.18

Current PS

4.93

Overvalued PS

186.81

Undervalued PS

-42.45

Financials

Annual

Quarterly

FY2025Q1

YoY :

+0.40%

499.00K

Total Revenue

FY2025Q1

YoY :

-42.39%

-31.03M

Operating Profit

FY2025Q1

YoY :

+6.17%

-52.89M

Net Income after Tax

FY2025Q1

YoY :

+3.61%

-0.86

EPS - Diluted

FY2025Q1

YoY :

-27.51%

-32.55M

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

-40.89%

-5.46K

FCF Margin - %

FY2025Q1

YoY :

+5.75%

-10.60K

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 555.03% over the last month.

Sold

0-3

Months

40.6K

USD

3-6

Months

25.7K

USD

6-9

Months

39.4K

USD

0-12

Months

130.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

120.3K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

953.0

Volume

Months

6-9

2.0K

Volume

Months

0-12

31.6K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areSelling! The selling amount has increased 555.03% over the last month.

Sold

0-3

Months

40.6K

USD

3-6

Months

25.7K

USD

6-9

Months

39.4K

USD

0-12

Months

130.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

IGMS News & Events

Events Timeline

2025-07-01 (ET)

2025-07-01

09:04:30

IGM Biosciences be acquired by Concentra for $1.247 in cash per share

2025-01-09 (ET)

2025-01-09

12:10:54

IGM Biosciences reducing workforce by 73%, evaluating strategic alternatives

2025-01-09

12:09:04

IGM Biosciences halting further development of imvotamab and IGM-2644

News

7.0

07-05Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OLO, SPTN, IGMS on Behalf of Shareholders

8.5

07-02Globenewswire

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of IGM Biosciences, Inc. (NASDAQ: IGMS)

7.0

07-01PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, IGMS, SPTN, DNOW on Behalf of Shareholders

People Also Watch

Bragg Gaming Group Inc

Atossa Therapeutics Inc

FAQ

What is IGM Biosciences Inc (IGMS) stock price today?

The current price of IGMS is 1.26 USD — it has decreased -0.79 % in the last trading day.

IGMS

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

IGMS News & Events

Events Timeline

News

People Also Watch

FAQ

What is IGM Biosciences Inc (IGMS) stock price today?

What is IGM Biosciences Inc (IGMS)'s business?

What is the price predicton of IGMS Stock?

What is IGM Biosciences Inc (IGMS)'s revenue for the last quarter?

What is IGM Biosciences Inc (IGMS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for IGM Biosciences Inc (IGMS)'s fundamentals?

How many employees does IGM Biosciences Inc (IGMS). have?

What is IGM Biosciences Inc (IGMS) market cap?